Talk:Vedolizumab

Cost
Vedolizumab (Entyvio) is one of those very expensive drugs that insurers often refuse to authorize. It was discussed in a story in ProPublica:

https://www.propublica.org/article/unitedhealth-healthcare-insurance-denial-ulcerative-colitis

UnitedHealthcare Tried to Deny Coverage to a Chronically Ill Patient. He Fought Back, Exposing the Insurer’s Inner Workings.

by David Armstrong, Patrick Rucker and Maya Miller

ProPublica

2 February 2023

It's hard to get a meaningful price for an expensive drug, but one reported figure in a WP:MEDRS was $406,629:

https://www.gastroenterologyandhepatology.net/archives/october-2016/the-cost-effectiveness-of-vedolizumab-for-inflammatory-bowel-disease-a-review-of-the-current-literature/

The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: A Review of the Current Literature

Gastroenterology & Hepatology

October 2016 12(10):617-621

Yecheskel Schneider, Monica Saumoy, Shirley Cohen-Mekelburg, Adam F. Steinlauf, and Ellen J. Scherl

--Nbauman (talk) 14:13, 28 June 2023 (UTC)


 * @Nbauman - Your comment implies that the drug costs much more than it does. It is pricey, alright, but per the Gastroenterology and Hepatology article you reference, the cost of vedolizumab was $301,969/MH. "MH" is defined as "The goals of biologic therapy are mucosal healing (MH) and reversal of the natural history of progressive structural damage due to chronic inflammation." That could happen over months or years.
 * Thank you, Wordreader (talk) 06:02, 27 December 2023 (UTC)